HLS Therapeutics Shares Dip 1.4% Amid New Analyst Ratings

Shares of HLS Therapeutics Inc. (TSE:HLS) experienced a decline of 1.4% during mid-day trading on Thursday, falling to a low of C$4.85 before rebounding slightly to a last traded price of C$4.92. Approximately 14,391 shares changed hands, marking a 5% increase from the average daily volume of 13,740 shares. The stock had previously closed at C$4.99.

Analysts Adjust Ratings and Price Targets

In a separate development, Raymond James Financial upgraded HLS Therapeutics from a “hold” rating to a “moderate buy” rating. The investment firm also raised its price target for the company from C$5.00 to C$6.00 in a research note published on August 21, 2023. Despite this positive outlook from Raymond James, one analyst continues to rate the stock as a “Hold.” According to MarketBeat, the consensus rating remains at “Hold,” with a target price of C$5.00.

Financial Metrics and Recent Performance

HLS Therapeutics holds a quick ratio of 1.01 and a current ratio of 1.56, indicating a reasonably healthy liquidity position. The company’s debt-to-equity ratio stands at 86.50, reflecting significant leverage. The market capitalization is approximately C$153.87 million, with a price-to-earnings ratio of -10.93 and a beta of 0.44.

The firm’s 50-day and 200-day simple moving averages are C$5.46 and C$5.15, respectively. HLS Therapeutics last reported its earnings on November 13, 2023, revealing an earnings per share (EPS) of C($0.12) for the quarter. The company reported revenue of C$18.81 million during this period. Analysts predict HLS Therapeutics will post an EPS of -0.12 for the current fiscal year.

As a specialty pharmaceutical company, HLS Therapeutics focuses on the acquisition and commercialization of branded pharmaceutical products within North America. Its portfolio includes treatment products for the central nervous system and cardiovascular specialties, featuring medications like Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia, and Perseris.

The fluctuations in HLS Therapeutics’ stock price, combined with recent analyst upgrades, indicate a dynamic environment for the company as it navigates the pharmaceutical market. Investors and stakeholders will be monitoring these developments closely as they unfold.